Navigation Links
Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change
Date:12/13/2014

Rockville, Maryland (PRWEB) December 12, 2014

Clarassance, a privately held clinical-stage biotechnology company based in Maryland, today announced its new name: Therabron Therapeutics, Inc. The new name is derived from the words therapy and bronchioles (a type of structure in the lungs similar to branches on a tree), thus incorporating the company’s mission to develop novel protein therapeutics for the treatment of respiratory diseases.

“Our board of directors decided to change the name to mark the company's escalation into the clinical phase in which multiple clinical trials will be performed,” said Dr. Aprile Pilon, founder and CEO of Therabron Therapeutics. “We think this new name will serve us well as we move forward in developing products to provide long-term improvement in a wide range of respiratory diseases.”

Therabron’s lead product candidate, recombinant human CC10 protein (rhCC10), is a synthetic version of the native CC10 protein, a potent anti-inflammatory factor that is deficient in many respiratory diseases. RhCC10 has completed two Phase 1 clinical trials in which it was shown to be safe in infants and adults. It showed potent anti-inflammatory activity and significant long-term benefit in premature infants, who are known to lack sufficient native CC10 in their lungs. Therabron is currently conducting a Phase 2 randomized trial of CG100 (rhCC10) in pre-term infants, who are at great risk for developing Bronchopulmonary Dysplasia (BPD), a chronic lung disease ranging in severity from mild asthma to life-threatening pulmonary fibrosis. The trial is over 30 percent enrolled and is projected to take another 12 months to complete enrollment of a total of 88 very premature infants. Therabron plans to initiate a second trial for its CG201 drug candidate in 2015.

About Therabron Therapeutics, Inc.
Therabron Therapeutics, Inc. is a clinical-stage biotechnology company, founded in 2007 and located in Rockville, MD, to develop protein drugs to treat respiratory diseases. The company’s products aim to restore the natural immune balance in the lungs of respiratory patients through the administration of synthetic human CC10 proteins. The family of CC10 proteins, also known as secretoglobins, have the potential to change the course of acute and chronic respiratory diseases, representing large markets into which few truly novel drugs have been introduced in the past several decades. Therabron’s products have the potential to be first-to-market, first-in-class, disease-modifying, break-through biologics. For additional information, please visit http://www.therabron.com.

Read the full story at http://www.prweb.com/releases/Therabon/Therapeutics/prweb12389881.htm.


'/>"/>
Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Related biology technology :

1. GenWay Biotech Launches New Cardiovascular Diagnostic Blood Test at American Heart Association Scientific Sessions 2011
2. Puma Biotechnology Announces Completion of Private Placement
3. Animal Biotechnology - Technologies, Markets and Companies
4. AtheroNova and Maxwell Biotech Group Ratify Agreement to Develop New Atherosclerosis Drug
5. The European Union Signs Grant Contract to Fund a 2 Million Euro Biotechnology Research Project Led by Hadassah College Jerusalem
6. Janssen Biotech, Inc. Announces Collaborative Development and Worldwide License Agreement for Investigational Anti-Cancer Drug, PCI-32765
7. Puma Biotechnology Announces Positive PB272 (Neratinib) Phase II Data at CTRC-AACR San Antonio Breast Cancer Symposium
8. Metamark Genetics Signs Collaboration Agreement on Novel Therapeutic Targets with Janssen Biotech
9. SuperNova Diagnostics® to Present at Biotech Showcase™ 2012 During JP Morgan Healthcare Conference January 9 - 12
10. Saladax Biomedical, Inc. to Present at Biotech Showcase™ 2012
11. Selexis SA to Present at Biotech Showcase 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... LAGUNA HILLS, Calif. , Oct. 11, 2017  SkylineDx ... London (ICR) and University of Leeds ... to risk-stratify patients with multiple myeloma (MM), in a multi-centric ... The University of Leeds is the ... UK, and ICR will perform the testing services to include ...
(Date:10/10/2017)... ... ... San Diego-based team building and cooking events company, Lajollacooks4u, has unveiled a ... new look is part of a transformation to increase awareness, appeal to new markets ... It will also expand its service offering from its signature gourmet cooking classes and ...
(Date:10/10/2017)... DALLAS , Oct. 10, 2017 International research firm ... IoT Strategy, will speak at the TMA 2017 Annual Meeting , ... key trends in the residential home security market and how smart safety ... ... "The ...
(Date:10/9/2017)... , Oct. 9, 2017  BioTech Holdings announced ... by which its ProCell stem cell therapy prevents ... ischemia.  The Company, demonstrated that treatment with ProCell ... limbs saved as compared to standard bone marrow ... HGF resulted in reduction of therapeutic effect.  ...
Breaking Biology Technology:
(Date:5/16/2017)... , May 16, 2017   Bridge Patient ... organizations, and MD EMR Systems , an ... partner for GE, have established a partnership to ... product and the GE Centricity™ products, including Centricity ... These new integrations will allow ...
(Date:4/18/2017)... Inc., a global expert in SoC-based imaging and computing solutions, has ... features the company,s hybrid codec technology. A demonstration utilizing TeraFaces ® ... be showcased during the upcoming Medtec Japan at Tokyo Big Sight ... Las Vegas Convention Center April 24-27. ... Click here for an image of the ...
(Date:4/11/2017)... , April 11, 2017 Crossmatch®, a ... authentication solutions, today announced that it has been ... Research Projects Activity (IARPA) to develop next-generation Presentation ... "Innovation has been a driving force ... program will allow us to innovate and develop ...
Breaking Biology News(10 mins):